Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
The concept of lifelong Lp(a) stability is challenged and consideration of repeated Lp(a) measurements in selected patients with established cardiovascular disease is supported.
Abstract
Lipoprotein(a) (Lp(a)) is traditionally regarded as a genetically determined and stable cardiovascular risk factor, often assumed to require only a single lifetime measurement. However, emerging evidence suggests that intra-individual Lp(a) levels may fluctuate over time. In this study, we aim to investigate the magnitude and prevalence of intra-individual Lp(a) variability in patients with established cardiovascular disease (CVD).
We analyzed longitudinal Lp(a) measurements from 1,570 CVD individuals(69.3% male)with baseline and follow-up testing between 2020 and 2025 at University Hospital Basel. Intra-individual Lp(a) variability was defined as an absolute change ≥25 nmol/L or a relative change ≥25%. Baseline Lp(a) levels were categorized as low (<75 nmol/L), intermediate (75–124 nmol/L), or high (≥125 nmol/L), and transitions between categories were assessed. Associations between Lp(a) variability with age, sex, BMI, lipids parameters, renal function, and follow-up duration were examined.
Baseline and follow-up Lp(a) levels were strongly correlated (Spearman ρ = 0.92, p < 0.001), indicating overall population-level stability. Nevertheless, 15.4% of individuals exhibited an absolute Lp(a) change ≥25 nmol/L and 34.6% demonstrated a relative change ≥25%. Notably, 36% of individuals with intermediate baseline Lp(a) transitioned to a different risk category at follow-up. Lp(a) variability was more pronounced in females aged between 42 and 80 years than males of the same age. Lp(a) variability occurred significantly more often when the interval between measurements exceeded 3.5 years. In multivariable logistic regression models incorporating restricted cubic splines, changes in LDL-C were independently associated with Lp(a) variability (P <0.01, nonlinear P < 0.01).
Intra-individual Lp(a) variability is substantial among CVD patients. Individuals with intermediate baseline Lp(a) levels are particularly prone to risk category reclassification. These findings challenge the concept of lifelong Lp(a) stability and support consideration of repeated Lp(a) measurements in selected patients.Graphical Summary
Lipoprotein(a) (Lp(a)) has emerged as an important cardiovascular risk factor and is expected to become modifiable through several Lp(a)-lowering therapies in the near future. Current guidelines recommend measuring Lp(a) at least once in a lifetime, as levels are considered largely genetically determined. However...
P. Siegel, M. Gissler, M. Buechsel et al.· European Heart Journal· 0 citations
Lp(a) shows a transient, non-linear increase during the acute phase of ACS associated with inflammatory response, and early post-ACS Lp(a) measurements may not reflect steady-state levels and should be interpreted cautiously.
S. Fujioka, K. Sakaguchi, H. Kusumoto et al.· European Heart Journal· 0 citations
The epidemiological, biological and methodological factors underlying variability in Lp(a) levels and their association with ASCVD across populations are explored, including the advantages and limitations of applying ancestry-specific Lp(a) risk thresholds.
B. Mansfield, F. Raal, Petri T. Kovanen et al.· Annals medicus· 0 citations
Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...
M. Szarek, D. L. Bhatt, M. Miller et al.· European Heart Journal· 0 citations
Lipoprotein(a) [Lp(a)] concentrations are mainly determined by genetic factors, yet evidence on their long-term variability and determinants remains limited, particularly among Asian populations.
This study examined temporal changes in Lp(a) concentrations and identified clinical predictors of substantial...
Di Chen, C. Chang, Ming-Lung Tsai· European Heart Journal· 0 citations